Compile Data Set for Download or QSAR
Report error Found 107 Enz. Inhib. hit(s) with all data for entry = 627
TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283143(US10023539, Example 9 | (2R)—N-[1-{N′-c...)
Affinity DataIC50: 2.64nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283194(US10023539, Example 29 | Rac-N-[1-(N′-cyano-...)
Affinity DataIC50: 5.55nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283173(N-[1-{N′-cyano-N-[2-methoxy-5-(trifluorometh...)
Affinity DataIC50: 6.65nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283196(US10023539, Example 31 | Rac-N-[1-(N′-cyano-...)
Affinity DataIC50: 9.09nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283172(US10023539, Example 19 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 9.98nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283169(US10023539, Example 18 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 12.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283143(US10023539, Example 9 | (2R)—N-[1-{N′-c...)
Affinity DataIC50: 13nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283139(US10023539, Example 7.2 | N-[1-{N′-cyano-N-[...)
Affinity DataIC50: 13.2nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283139(US10023539, Example 7.2 | N-[1-{N′-cyano-N-[...)
Affinity DataIC50: 13.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283132(US10023539, Example 3 | Rac-N-[1-{N′-cyano-N...)
Affinity DataIC50: 15nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283195(US10023539, Example 30 | Rac-N-[r-(N′-cyano-...)
Affinity DataIC50: 15.8nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283184(N-[1-{N′-cyano-N-[3-(difluoromethoxy)-5-fluo...)
Affinity DataIC50: 19.2nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283172(US10023539, Example 19 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 21.3nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283205(N-[3-(4-Chloro-3-methylphenyl)-1-{N′-cyano-N...)
Affinity DataIC50: 22.9nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283173(N-[1-{N′-cyano-N-[2-methoxy-5-(trifluorometh...)
Affinity DataIC50: 23.6nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283197(US10023539, Example 32 | Rac-N-[1-(N′-cyano-...)
Affinity DataIC50: 26.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283169(US10023539, Example 18 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 27.7nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50181508(CHEMBL3818083 | US10023539, Example 4.2)
Affinity DataIC50: 28.2nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50181508(CHEMBL3818083 | US10023539, Example 4.2)
Affinity DataIC50: 28.2nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283170(N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-meth...)
Affinity DataIC50: 28.7nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283170(N-[1-{N′-cyano-N-[5-(difluoromethoxy)-2-meth...)
Affinity DataIC50: 30nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283189(US10023539, Example 26 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 30.6nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283208(US10023539, Example 38 | N-[1-{N′-cyano-N-[3...)
Affinity DataIC50: 32nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283209(US10023539, Example 38.2 | N-[1-{N′-cyano-N-...)
Affinity DataIC50: 35.6nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283208(US10023539, Example 38 | N-[1-{N′-cyano-N-[3...)
Affinity DataIC50: 37.2nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283209(US10023539, Example 38.2 | N-[1-{N′-cyano-N-...)
Affinity DataIC50: 37.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50180974(CHEMBL3818092 | US10023539, Example 33.2)
Affinity DataIC50: 37.6nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283204(US10023539, Example 36 | rac-N-[3-(4-Chloro-3-meth...)
Affinity DataIC50: 40.7nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283150(N-[1-{N-[4-chloro-3-(difluoromethoxy)phenyl]-NR...)
Affinity DataIC50: 44.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50181508(CHEMBL3818083 | US10023539, Example 4.2)
Affinity DataIC50: 46.7nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283159(N-[1-{N′-cyano-N-[3-(trifluoromethoxy)phenyl...)
Affinity DataIC50: 50nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283179(N-[1-{N′-cyano-N-[3-(2,2,2-trifluoroethyl)ph...)
Affinity DataIC50: 53nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283156(N-[1-{N′-cyano-N-[2-fluoro-3-(trifluorometho...)
Affinity DataIC50: 54.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283168(US10023539, Example 17 | Rac-N-[1-(N′-cyano-...)
Affinity DataIC50: 59.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283183(US10023539, Example 24 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 63.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283181(US10023539, Example 22 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 64.8nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283182(US10023539, Example 23 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 67.4nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283163(N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimid...)
Affinity DataIC50: 71nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283191(N-[1-{N′-cyano-N-[2-(pyrrolidin-1-ylmethyl)-...)
Affinity DataIC50: 73.2nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283214(US10023539, Example 41 | N-[1-{N′-Cyano-N-[3...)
Affinity DataIC50: 73.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283133(US10023539, Example 4 | Rac-N-[1-{N′-cyano-N...)
Affinity DataIC50: 82.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283131(US10023539, Example 2 | Rac-N-[1-{N′-cyano-N...)
Affinity DataIC50: 83.3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283198(US10023539, Example 33 | Rac-N-[3-(4-chloro-3-meth...)
Affinity DataIC50: 84.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283158(US10023539, Example 13 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 86.7nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283142(US10023539, Example 8 | (2S)—N-[1-{N′-c...)
Affinity DataIC50: 90.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283190(US10023539, Example 27 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 95.9nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM50180974(CHEMBL3818092 | US10023539, Example 33.2)
Affinity DataIC50: 96.4nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283163(N-{1-[N′-cyano-N-(3-methoxyphenyl)carbamimid...)
Affinity DataIC50: 99.6nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283132(US10023539, Example 3 | Rac-N-[1-{N′-cyano-N...)
Affinity DataIC50: 101nMAssay Description:For the detection of SMYD2 cellular methylation activity an In Cell Western (ICW) assay was established. This assay allows rapid processing of multip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

TargetN-lysine methyltransferase SMYD2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM283186(US10023539, Example 25 | Rac-N-[1-{N′-cyano-...)
Affinity DataIC50: 108nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/6/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 107 total ) | Next | Last >>
Jump to: